The impact of glucocorticoids and anti-cd20 therapy on cervical human papillomavirus infection risk in women with systemic lupus erythematosus

Clinics

Volumn 68, Issue 12, 2013, Pages 1475-1480

  Mendoza Pinto, Claudia ^a   Garcia Carrasco, Mario ^a,b   Vallejo Ruiz, Veronica ^a   Taboada Cole, Alejandro ^a   Muñoz Guarneros, Margarita ^b   Solis Poblano, Juan Carlos ^a   Pezzat Said, Elias ^b   Aguilar Lemarroy, Adriana ^c   Jave Suarez, Luis Felipe ^c   de Lara, Luis Vazquez ^b   Ramos Alvarez, Gloria ^a   Reyes Leyva, Julio ^a   Lopez Colombo, Aurelio ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA DE OCCIDENTE   (Mexico)

Author keywords

Cervical human papillomavirus infection; Risk factors; Rituximab; Systemic lupus erythematosus

Indexed keywords

GLUCOCORTICOID; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; RITUXIMAB; VIRUS DNA;

ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; CYTOLOGY; FEMALE; GENOTYPE; HUMAN; MEXICO; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; RISK FACTOR; SOCIOECONOMICS; STATISTICAL MODEL; SYSTEMIC LUPUS ERYTHEMATOSUS; UTERINE CERVIX; UTERINE CERVIX DISEASE; VAGINA SMEAR; VIROLOGY;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CERVIX UTERI; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; GENOTYPE; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEXICO; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREVALENCE; RISK FACTORS; SOCIOECONOMIC FACTORS; UTERINE CERVICAL DISEASES; VAGINAL SMEARS;

EID: 84892764295     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(12)01     Document Type: Article

References (38)

1. Dhar JP, Kmak D, Bhan R, Pishorodi L, Ager J, Sokol RJ. Abnormal cervicovaginal cytology in women with lupus: a retrospective cohort study. Gynecol Oncol. 2001;82(1):4-6, http://dx.doi.org/10.1006/gyno.2001.6207.
2. Blumenfeld Z, Lorber M, Yoffe N, Scharf Y. Systemic lupus erythematosus: predisposition for uterine cervical dysplasia. Lupus. 1994;3(1):59-61, http://dx.doi.org/10.1177/096120339400300112.
3. Tam LS, Chan AY, Chan PK, Chang AR, Li EK. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum. 2004;50(11):3619-3625, http://dx.doi.org/10.1002/art.20616.
4. Nath R, Mant C, Luxton J, Hughes G, Raju KS, Shepherd P, et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum. 2007;57(4):619-625,http://dx.doi.org/10.1002/art.22667.
5. Rojo-Contreras W, Olivar-Flores EM, Gamez-Nava JI, Montoya-Fuentes H, Trujillo-Hernandez B, Suarez-Rincon AE, et al. Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis. Lupus. 2012;21(4):365-372, http://dx.doi.org/10.1177/0961203311425517.
6. Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, et al. Cancer risk in systemic lupus: An updated international multicentre cohort study. J Autoimmun. 2013;42:130-135,http://dx.doi.org/10.1016/j.jaut.2012.12.009.
7. Bernatsky S, Clarke AE, Petri MA, Urowitz MB, Fortin PR, Gladman DD, et al. Further defining cancer risk in systemic lupus: updated results in an expanded international multi-centre cohort [abstract]. Arthritis Rheum. 2010;62(Suppl.):S731.
8. Santana IU, Gomes AD, Lyrio LD, Rios Grassi MF, Santiago MB. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol. 2010;30(5):665-672.
9. Lyrio LD, Grassi MF, Santana IU, Olavarria VG, Gomes AD, Costapinto L, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int. 2013;33(2):631-636.
10. Matteucci P, Magni M, Di Nicola M, Carlo-Stella C, Uberti C, Gianni AM. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood. 2002;100 (3):1104-1105, http://dx.doi.org/10.1182/blood-2002-04-1271.
11. Flores Y, Bishai D, Lazcano E, Shah K, Lorincz A, Hernández M, Salmerón J. Improving cervical cancer screening in México: results from the Morelos HPV Study. Salud Publica Mex. 2003;45:S3:388-98, http://dx.doi.org/10.1590/S0036-36342003000900013.
12. Kuri-Morales P, Emberson J, Alegre-Díaz J, Tapia-Conyer R, Collins R, Peto R, et al. The prevalence of chronic diseases and major disease risk factors at different ages among 150,000 men and women living in México City: cross-sectional analyses of a prospective study. BMC Public Health. 2009;9:9, http://dx.doi.org/10.1186/1471-2458-9-9.
13. Zonana-Nacach A, Yañez P, Jiménez-Balderas FJ, Camargo-Coronel A. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus. Lupus. 2007;16(12):997-1000, http://dx.doi.org/10.1177/0961203307083175.
14. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum. 1997;40(9):1725, http://dx.doi.org/10.1002/art.1780400928.
15. Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol. 1992;19(19):1551-1558.
16. Galdman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363-369, http://dx.doi.org/10.1002/art.1780390303.
17. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(6):2114-2119,http://dx.doi.org/10.1001/jama.287.16.2114.
18. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38(1):357-361.
19. van den Brule AJ, Meijer CJ, Bakels V, Kenemans P, Walboomers JM. Rapid detection of human papillomavirus in cervical scrapes by combined general primer-mediated and type-specific polymerase chain reaction. J Clin Microbiol. 1990;28(12):2739-2743.
20. Yasojima K, Kilgore KS, Washington RA, Lucchesi BR, McGeer PL. Complement gene expression by rabbit heart: upregulation by ischemia and reperfusion. Circ Res. 1998;82(11):1224-1230,http://dx.doi.org/10.1161/01.RES.82.11.1224.
21. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527.
22. Tam LS, Chan PK, Ho SC, Yu MM, Yim SF, Cheung TH, et al. Natural history of cervical papilloma virus infection in systemic lupus erythematosus a prospective cohort study. J Rheumatol. 2010;37(2): 330-340, http://dx.doi.org/10.3899/jrheum.090644.
23. Orozco-Colin A, Carrillo-Garcia A, Mendez-Tenorio A, Ponce-de-León S, Mohar A, Maldonado-Rodríguez R, et al. Geographical variation in human papillomavirus prevalence in Mexican women with normal cytology. Int J Infect Dis. 2010;14(12):1082-1087.
24. Klumb EM, Pinto AC, Jesus GR, Araujo M Jr, Jascone L, Gayer CR, et al. Are women with lupus at higher risk of HPV infection? Lupus. 2010;19(13):1485-1491, http://dx.doi.org/10.1177/0961203310372952.
25. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med. 2003;348(6):489-490.
26. Febronio MV, Pereira RM, Bonfa E, Takiuti AD, Pereyra EA, Silva CA. Inflammatory cervicovaginal cytology is associated with disease activity in juvenile systemic lupus erythematosus. Lupus. 2007;16(6):430-435, http://dx.doi.org/10.1177/0961203307079298.
27. Yu SL, Chan PK, Wong CK, Szeto CC, Ho SC, So K, et al. Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus. Arthritis Res Ther. 2012;14(2):R80, http://dx.doi.org/10.1186/ar3803.
28. Boor PP, Metselaar HJ, Mancham S, Tilanus HW, Kusters JG, Kwekkeboom J. Prednisolone suppresses the function and promotes apoptosis of plasmacytoid dendritic cells. Am J Transplant. 2006;6 (10):2332-2341.
29. Takata T, Suzumiya J, Ishikawa T, Takamatsu Y, Ikematsu H, Tamura K. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin Bcell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematop. 2009;49(1):9-13, http://dx.doi.org/10.3960/jslrt.49.9.
30. Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2008;67(7):937-941.
31. Gelinck LB, Teng YK, Rimmelzwaan GF, Van den Bemt BJ, Kroon FP, van Laar JM. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis. 2007;66(10):1402-1403, http://dx.doi.org/10.1136/ard.2007.071878.
32. Abud-Mendoza C, Cuevas-Orta E, Santillán-Guerrero EN, Martínez-Martínez MU, Hernández-Castro B, Estrada-Capetillo L, et al. Decreased blood level of B lymphocytes and NK cells in patients with systemic lupus erythematosus (SLE) infected with papillomavirus (HPV). Arch Dermatol Res. 2013;305(2):117-123, http://dx.doi.org/10.1007/s00403-012-1258-9.
33. Ognenovski VM, Marder W, Somers EC, Johnston CM, Farrehi JG, Selvaggi SM, et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with cyclophosphamide. J Rheumatol. 2004;31(9):1763-1767.
34. Bateman H, Yazici Y, Leff L, Peterson M, Paget SA. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus. 2000;9(7):542-544, http://dx.doi.org/10.1177/096120330000900711.
35. Shoenfeld Y. Infections, vaccines and autoimmunity. Lupus. 2009;18(13): 1127-1128, http://dx.doi.org/10.1177/0961203309351081.
36. O'Connor MB, Bond U, Phelan MJ. The impact of human papillomavirus and human papillomavirus vaccination among rheumatology patients. J Clin Rheumatol. 2010;16(7):355.
37. Soldevilla HF, Briones SFR, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus. 2012;21(2):158-161, http://dx.doi.org/10.1177/0961203311429556.
38. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72(5): 659-664, http://dx.doi.org/10.1136/annrheumdis-2012-201393.